2022 ASCO Annual Meeting*

At a median follow-up of 2.3 years, asciminib continues to show deeper and more durable responses with more favorable safety compared with bosutinib among patients with CML-CP previously treated with ≥2 TKIs.

Comutational profiles and survival benefits from enasidenib appear to differ based on presence of the IDH2 R140 or IDH2 R172 mutation, warranting additional research to clarify the influence of the various mutations on treatment outcomes.

In this retrospective analysis of CIBMTR-collected blood samples, NGS-MRD detection of NPM1 mutations and/or FLT3-ITD was associated with significant prognostic value for relapse and survival in patients with AML in first remission prior to allogeneic HCT.

Patients with newly diagnosed FLT3-mutated AML demonstrated high overall response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 after a median follow-up of 45 months.

The chemotherapy-free combination of ponatinib and blinatumomab has demonstrated high response rates, including deep and durable responses, in patients with newly diagnosed and relapsed/refractory Ph+ ALL.

Among older adults newly diagnosed with Ph-negative B-cell ALL, mini-hyperCVD plus inotuzumab with or without blinatumomab was associated with a 5-year OS rate of 47%.

In this single-arm study, magrolimab plus azacitidine had a tolerable safety profile and achieved a CR rate of 33% in the frontline treatment of patients with TP53-mutated AML not eligible for intensive induction therapy.

This pivotal phase II trial of glofitamab in patients with heavily pretreated, refractory DLBCL demonstrated a CR rate of 39.4%, with similar CR rates with or without previous CAR T-cell therapy.

With approximately 6 years of follow-up of ECHELON-1, addition of brentuximab vedotin to AVD significantly improved overall survival vs ABVD in patients with previously untreated advanced cHL.

Results of the ROSEWOOD trial suggest a favorable risk–benefit ratio for zanubrutinib and obinutuzumab, as indicated by improved ORR, DoR, PFS, and OS compared with obinutuzumab alone and no unexpected safety signals.

Preliminary data suggest that combined treatment with anti–PD-1 and anti–LAG-3 agents provides antitumor activity with a high response rate and durable responses in patients with R/R classical Hodgkin lymphoma naive to anti–PD-1 treatment.

The 3-year update of the CAPTIVATE fixed-duration cohort continues to show deep and durable responses with first-line ibrutinib + venetoclax in CLL/SLL including in patients with high-risk features.

In a phase I/II trial, zilovertamab plus ibrutinib was generally well tolerated with robust efficacy compared with historical data for ibrutinib alone in MCL or CLL.

In this updated analysis of the patient cohort with newly diagnosed high-risk DLBCL, epcoritamab SC combined with R-CHOP had a manageable safety profile and yielded an ORR of 100% and a CMR of 77%.

In this updated analysis of the cohort with relapsed/refractory follicular lymphoma enrolled on an ongoing phase I/II trial, epcoritamab in combination with rituximab and lenalidomide was associated with a manageable safety profile and an ORR of 100%.

After a median follow-up of approximately 4 years, acalabrutinib maintained significantly improved PFS with no new safety concerns vs standard-of-care regimens in patients with relapsed/refractory CLL.

After a median follow-up of approximately 5 years, acalabrutinib-based combination therapy and monotherapy maintained significantly improved PFS vs chemoimmunotherapy in patients with treatment-naive CLL with no new safety concerns.

In this interim analysis, use of post-ASCT carfilzomib/lenalidomide/dexamethasone with an MRD-directed, risk-adapted approach was associated with an improvement in PFS vs standard lenalidomide maintenance.

Updated results from this investigator-initiated study suggest that GC012F confers rapid, deep, durable responses among high-risk and heavily pretreated patients with relapsed/refractory multiple myeloma.

Teclistamab was associated with a high response rate and durable responses in patients with highly refractory MM not previously treated with BCMA-targeted therapy.

In the phase III DETERMINATION trial, addition of ASCT to VRd induction with ongoing lenalidomide maintenance resulted in prolonged median PFS—but not OS—in newly diagnosed multiple myeloma.

The addition of ibrutinib to chemoimmunotherapy prolonged median PFS by 2.3 years in older, previously untreated patients with MCL.